Acta Scientific Pharmaceutical Sciences

Short CommunicationVolume 2 Issue 8

Zostavax vs. Shingrix – Which Should Pharmacists Recommend

Ali Chaudhry*

Shoppers Drug Mart, Thunder Bay, Canada

*Corresponding Author: Ali Chaudhry, Shoppers Drug Mart, Thunder Bay, Canada.

Received: June 22, 2018; Published: July 03, 2018

Citation: Ali Chaudhry.“Zostavax vs. Shingrix – Which Should Pharmacists Recommend”. Acta Scientific Pharmaceutical Sciences 2.8 (2018).

   With the release of the new vaccine Shingrix for the prevention of shingles and postherpetic neuralgia, it begs the question as to whether this new vaccine is any better than the current vaccine, Zostavax. Pharmacists are in a unique position to help identify patients who are at risk of developing shingles, and by knowing which vaccine is better suited for a patient, can potentially help a patient from long term suffering.

Copyright: © 2018 Ali Chaudhry. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Member In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 15, 2020.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US